NCT04857437View on ClinicalTrials.gov

Study in Healthy Adults Evaluating PF-07202954

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 13, 2021

Primary Completion Date

September 17, 2021

Study Completion Date

September 17, 2021

Conditions
Non-Alcoholic Fatty Liver DiseaseLiver Fibrosis
Interventions
DRUG

PF-07202954 Repeat Dose

10, 30, 100, 300, 600, 1200 milligrams (mg)

DRUG

PF-07202954 Single Dose

10, 30, 100, 300, 600, 900, 1200 milligrams (mg)

DRUG

Placebo

Matching Placebo

Trial Locations (1)

06511

New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY